FindTrial
Sign In

Treatment Alternatives for Drug-naïve Schizophrenia in Japan

Treatment Alternatives for Drug-naïve Schizophrenia in Japan - TADS-J

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000002228
Enrollment
600
Registered
2009-07-21
Start date
2009-04-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia

Interventions

Treatment with aripiprazole for 8 weeks

Sponsors

Resarch enforcement group, Japanese Sciety of Clinical Neuropsychopharmacology
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1)schizophrenia and brief psychosis 2)patients with 60 points or more than 60 points

Exclusion criteria

Exclusion criteria: 1)Patinets with organic illness 2)Patinets with diabetis 3)Patinets with mental ritardation 4)Patinets who have mediation histrory with antipsychotics within 1 month 5)Patinets with severe suicidal thought

Design outcomes

Primary

MeasureTime frame
improvement of schizophrenia symptoms—

Secondary

MeasureTime frame
adverse effects—

Countries

Japan

Contacts

Public ContactNorio Yasui-Furukori

Graduate School of Medicine, Hirosaki University Department of Neuropsychiatry

yasufuru@cc.hirosaki-u.ac.jp0172-33-5111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026